X

Drug Profile

RWJ 68023

Alternative Names: Motilin receptor antagonists - Johnson & Johnson; RWJ-68023

Latest Information Update: 16 Jul 2016

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Johnson & Johnson Pharmaceutical Research & Development
Class Irritable bowel syndrome therapies
Mechanism of Action Motilin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Dyspepsia; Irritable bowel syndrome

Most Recent Events

16 Jul 2016 No recent reports of development identified for phase-I development in Dyspepsia in USA (PO)
16 Jul 2016 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in USA (PO)
11 Oct 2004 Phase-I clinical trials in Dyspepsia in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com